BD Says Biosciences Revenue Jumps 9 Percent in Fiscal Q3 as R&D Spend Soars | GenomeWeb
NEW YORK (GenomeWeb News) – Becton Dickinson today said fiscal third-quarter revenue increased 7 percent as R&D costs soared 42 percent and income grew 9 percent.
 
Receipts for the three months ended June 30 increased to $1.5 billion from $1.4 billion year over year.
 
The BD Biosciences segment reported the strongest growth, as revenues increased 9 percent to $219 million. Sales of flow cytometry instruments, reagents, and cell imaging products contributed to the rise.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.